If low nephron endowment is a contributor to some presentations of insidious APOL1 kidney disease, the current anti-APOL1 drugs in clinical testing may be ineffective in these cases since ongoing APOL1 expression is not driving podocyte loss and the ensuing proteinuria and eGFR decline. Here, APOL1 is linked to kidney disorder.